SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/04/21 Bristol Myers Squibb Co. 8-K:5,9 3/01/21 11:212K Edgarfilings Ltd. |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 31K 7: R1 Document and Entity Information HTML 57K 9: XML IDEA XML File -- Filing Summary XML 12K 6: XML XBRL Instance -- brhc10021324_8k_htm XML 25K 8: EXCEL IDEA Workbook of Financial Reports XLSX 6K 3: EX-101.DEF XBRL Definitions -- bmy-20210301_def XML 52K 4: EX-101.LAB XBRL Labels -- bmy-20210301_lab XML 79K 5: EX-101.PRE XBRL Presentations -- bmy-20210301_pre XML 56K 2: EX-101.SCH XBRL Schema -- bmy-20210301 XSD 17K 10: JSON XBRL Instance as JSON Data -- MetaLinks 16± 22K 11: ZIP XBRL Zipped Folder -- 0001140361-21-007317-xbrl Zip 14K
i Delaware
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
i 22-0790350
(IRS Employer Identification Number)
|
i 430 East 29th Street, i 14th Floor
i New York, i NY, i 10016
(Address of Principal Executive Office)
|
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
i Common Stock, $0.10 Par Value
|
i BMY |
i New York Stock Exchange
|
i 1.000% Notes due 2025 |
i BMY25 |
i New York Stock Exchange
|
i 1.750% Notes due 2035
|
i BMY35 |
i New York Stock Exchange
|
i Celgene Contingent Value Rights
|
i CELG RT |
i New York Stock Exchange
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 9.01. |
Financial Statements and Exhibits.
|
Exhibit
No.
|
Description
|
||
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
Exhibit
No.
|
Description
|
||
104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
|
BRISTOL-MYERS SQUIBB COMPANY
|
|||
Dated: March 4, 2021
|
By:
|
||
Name:
|
|||
Title:
|
Corporate Secretary
|
||
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
5/4/21 | 8-K, DEF 14A, PRE 14A, S-8, S-8 POS | |||
Filed on: | 3/4/21 | |||
For Period end: | 3/1/21 | 4 | ||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/16/24 Bristol-Myers Squibb Co. 424B5 2:1.2M Broadridge Fin’l So… Inc 2/13/24 Bristol-Myers Squibb Co. 424B2 1:856K Broadridge Fin’l So… Inc 11/01/23 Bristol-Myers Squibb Co. 424B5 2:927K Broadridge Fin’l So… Inc 10/30/23 Bristol-Myers Squibb Co. 424B3 1:818K Broadridge Fin’l So… Inc 2/17/22 Bristol-Myers Squibb Co. 424B5 2:878K Broadridge Fin’l So… Inc 2/15/22 Bristol-Myers Squibb Co. 424B3 1:789K Broadridge Fin’l So… Inc 12/13/21 Bristol-Myers Squibb Co. S-3ASR 12/13/21 4:554K Broadridge Fin’l So… Inc 5/04/21 Bristol-Myers Squibb Co. S-8 5/04/21 3:81K Broadridge Fin’l So… Inc 5/04/21 Bristol-Myers Squibb Co. S-8 POS 5/04/21 3:85K Broadridge Fin’l So… Inc |